PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Report Buyer Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Monoclonal Antibodies Are the Fastest Growing Segment in Pharmaceutical Industry Says New Report - Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which finds that the Monoclonal Antibodies (mAb) market has overcome its shaky beginnings twenty years ago
Monoclonal Antibodies Are the Fastest Growing Segment in Pharmaceutical Industry Says New Report

 

NewswireToday - /newswire/ - London, United Kingdom, 2007/10/18 - Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which finds that the Monoclonal Antibodies (mAb) market has overcome its shaky beginnings twenty years ago.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which finds that the Monoclonal Antibodies (mAb) market has overcome its shaky beginnings twenty years ago to currently generate global revenues of about $20 billion.

“Monoclonal Antibodies Report Part I” finds that mAbs are the fastest-growing segment within the pharmaceutical industry, and are expected to achieve a compound annual growth rate (CAGR) of 14% between 2006- 2012. The study says this puts the mAb market far ahead of the small molecules market.

Several factors have played a role in the success of the mAb market. One of the most important factors is the evolution of antibody technology which makes current blockbuster products chimeric or humanised mAbs, and so far removed from the murine (mouse derived) products that were first introduced.

Analysts say that mAb drug developers have also launched a range of mAb products after the phenomenal commercial success of Rituxan/MabThera for non-Hodgkin's lymphoma (NHL) in 1997. The launches of key products such as Avastin, Herceptin, Remicade, MabThera/Rituxan, Humira and Erbitux have placed the market at an inflection point of maximum sales growth.

Also driving the revenue expansion in the market will be the launch of new products like UCB-Celltech's Cimzia (certolizumabpegol) for Crohn's disease and rheumatoid arthritis. Significant market products like Genentech and Roche's Avastin (bevacizumab) with a broad–spectrum mode of action will be used to target a wide range of tumour types.

Authors of the report cite the example of just five monoclonal antibody products - Avastin, Herceptin, Humira, Remicade and Rituxan - accounting for 80% of total mAb revenues in 2006, and predict that these big five will continue to dominate the market in the next five years allowing Genentech/Roche, which has ownership of three of the big five, to retain their stranglehold over the mAb market.

The study says however that market growth could slow down post 2012 as a result of competition between rival mAb products and second-generation product launches eating into the sales of first-generation mAb products.

The report analyses the mAb market assessing trends by product, company, therapy area, technology and target type. It also shows how mAb technology is evolving and compares pipeline products. The study identifies the key products that will drive sales growth in the mAb market to 2012 and outlines challenges for new players entering the market.

“Monoclonal Antibodies Report Part I” is available from Report Buyer. For more information, please visit the website.

Report Buyer product ID: DAT05897

About Report Buyer
Report Buyer is a UK-based independent online store supplying business information on major industry sectors. These include the Automotive Industry, Banking & Finance, Energy & Utilities, Food & Drink, Telecoms and Pharma & Healthcare. The website now carries over 40,000 business information products, including market reports, studies and books. Report Buyer is the intelligent way to buy market research making it an essential resource for executives and information buyers worldwide. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Report Buyer Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Monoclonal Antibodies Are the Fastest Growing Segment in Pharmaceutical Industry Says New Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Urmila Doraswami 
+44 (0) 20 7060 7474 press[.]reportbuyer.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Report Buyer Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Report Buyer Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)